There are currently 16 active clinical trials seeking participants for Primary Sclerosing Cholangitis research studies. The states with the highest number of trials for Primary Sclerosing Cholangitis participants are California, Virginia, Texas and Florida.
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection o... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
A Study of SIPLIZUMAB in AILD and LT Patients
NCT06455280
Recruiting
There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York, New York
Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Register for Updates
Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis
NCT03561584
Recruiting
This is a multicenter, randomized, double-blinded placebo controlled trial to assess the benefit of sulfasalazine in the treatment of PSC. The specific objectives of this study are to determine if sulfasalazine treatment 1) results in reduced serum ALP and other biomarkers of liver injury in PSC; 2) improves PSC patient symptoms; and 3) is safe in patients with PSC. We are recruiting remotely throughout the United States so an individual anywhere in the US with PSC and IBD can be enrolled.
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
04/19/2024
Locations: Brigham and Women's Hospital, Chestnut Hill, Massachusetts
Conditions: Primary Sclerosing Cholangitis
Register for Updates
Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
NCT02137668
Recruiting
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Gender:
ALL
Ages:
Between 2 weeks and 40 years
Trial Updated:
11/10/2016
Locations: Sacramento Pediatric Gastroenterology, Sacramento, California
Conditions: Primary Sclerosing Cholangitis, Biliary Atresia
Register for Updates